PBA
LXEO icon

Paradigm Biocapital Advisors’s Lexeo Therapeutics LXEO Stock Holding History

Paradigm Biocapital Advisors’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4M Sell
4,175,382
-2,008,752
-32% -$10.9M 0.36% 26
2026
Q1 		$35.5M Buy
6,184,134
+1,420,936
+30% +$10.1M 0.73% 26
2025
Q4 		$47.3M Buy
+4,763,198
New +$43.5M 1.21% 21

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Paradigm Biocapital Advisors's LXEO Position: Q2 2026 in Review

Paradigm Biocapital Advisors reduced its Lexeo Therapeutics (LXEO) stake by 32% in Q2 2026, selling an estimated $10.9M and leaving 4,175,382 shares worth $19.4M. The position accounts for 0.36% of the portfolio, ranked #26.

Paradigm Biocapital Advisors first reported a position in LXEO in Q4 2025 and has held it in 3 quarters since. The position peaked at $47.3M in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Paradigm Biocapital Advisors held 4,175,382 shares of Lexeo Therapeutics worth $19.4M as of Q2 2026.
  • Paradigm Biocapital Advisors sold 2,008,752 Lexeo Therapeutics shares in Q2 2026, an estimated $10.9M.
  • Lexeo Therapeutics made up 0.36% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #26 holding.
  • Paradigm Biocapital Advisors first reported a position in Lexeo Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Paradigm Biocapital Advisors's Lexeo Therapeutics position peaked at $47.3M in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.